GLP-1 medications are highly effective, but the rapid changes they drive in appetite and weight create predictable nutritional challenges. This article covers those challenges and what the evidence says about addressing them.
Common Issues During GLP-1 Therapy
- Severe appetite suppression leading to insufficient protein, vitamin, and mineral intake.
- Nausea and GI disturbance — the most common side effect, affecting 30–40% of users.
- Muscle mass loss — approximately 38–40% of the weight lost during GLP-1 therapy is lean mass, a clinically significant concern.
- Bone-density concerns associated with rapid weight loss.
- Nutrient deficiencies — B12, iron, folate, calcium, and vitamin D are the most common.
Protein — The First Priority
Protein is the single most important nutritional intervention during GLP-1 therapy. Aim for at least 1.2–1.6g of protein per kilogram of body weight daily. Most GLP-1 users struggle to reach this target because of appetite suppression, and a protein-tracking app can help. Protein is technically food rather than a supplement, but it belongs at the top of this list.
Creatine Monohydrate — Muscle Preservation
A Cochrane systematic review and multiple meta-analyses support creatine combined with resistance training for preserving lean mass — particularly relevant for GLP-1 users, who are at elevated risk of muscle loss. The dose is 3–5g daily. Creatine is the most extensively studied supplement in existence and has an excellent safety profile. Note that serum creatinine rises modestly with creatine use; this is a metabolic byproduct, not a sign of kidney damage.
Vitamin B12 (Methylcobalamin)
GLP-1 drugs do not directly deplete B12, but severely reduced food intake can lead to deficiency. 1,000mcg daily of sublingual or oral methylcobalamin is reasonable. Monitor serum B12 with your physician.
Magnesium Glycinate
Magnesium is frequently low in the general population, and reduced food intake during GLP-1 therapy compounds the gap. 300–400mg of elemental magnesium as glycinate daily is a reasonable target. See our full magnesium article for details on forms and dosing.
Vitamin D3 + K2
Because rapid weight loss affects bone density, vitamin D status matters. 2,000–4,000 IU of vitamin D3 daily, paired with K2 (MK-7 form) at 100mcg to support calcium utilization, is a common evidence-based approach.
This site contains affiliate links. If you purchase through our link we may earn a commission at no extra cost to you.
Creatine monohydrate combined with resistance training is the gold standard evidence-based approach for muscle preservation during GLP-1 therapy:
View Creatine Monohydrate on Amazon →Sources
- SELECT Trial (2023). New England Journal of Medicine. Semaglutide cardiovascular outcomes.
- SURMOUNT-1 Trial. Tirzepatide weight loss and body-composition data.
- Heymsfield et al. Lean-mass loss data in GLP-1 trials.
- Cochrane Review: creatine supplementation and lean mass.